Abhinav Deol1, Lawrence G Lum. 1. Blood and Marrow Stem Cell Transplantation and Immunotherapy Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 4th Floor, Hudson Webber Cancer Research Center, 4100 John R., Detroit, MI 48201, USA.
Abstract
BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) from the stem cell donor is an attractive clinical option to salvage this group of patients. METHODS: We reviewed the important studies looking at donor lymphocyte infusion as a therapy for the treatment of hematological disorders that are either refractory to or have relapsed after allogeneic SCT. RESULTS: The response to DLI is dependent upon type of disease, dose of infused lymphocytes, and the development of graft vs. host disease (GvHD). The best response rates are seen in patients with chronic myeloid leukemia (CML) followed by patients with lymphomas, multiple myeloma and acute leukemias, respectively. The responses in patients with CML are durable whereas durable responses in other diseases are rare. CONCLUSIONS: Given the development of new drugs to treat some hematological diseases, DLI has taken a backseat. New modalities to target the infused cells to the tumor and new approaches to reduce GvHD that will augment the graft vs. leukemia/lymphoma (GvL) effect and decrease the injury to normal host tissues need to be developed. Understanding the factors and mechanisms that differentiate the GvL effect from GvHD will help in the development of newer treatment modalities.
BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) from the stem cell donor is an attractive clinical option to salvage this group of patients. METHODS: We reviewed the important studies looking at donor lymphocyte infusion as a therapy for the treatment of hematological disorders that are either refractory to or have relapsed after allogeneic SCT. RESULTS: The response to DLI is dependent upon type of disease, dose of infused lymphocytes, and the development of graft vs. host disease (GvHD). The best response rates are seen in patients with chronic myeloid leukemia (CML) followed by patients with lymphomas, multiple myeloma and acute leukemias, respectively. The responses in patients with CML are durable whereas durable responses in other diseases are rare. CONCLUSIONS: Given the development of new drugs to treat some hematological diseases, DLI has taken a backseat. New modalities to target the infused cells to the tumor and new approaches to reduce GvHD that will augment the graft vs. leukemia/lymphoma (GvL) effect and decrease the injury to normal host tissues need to be developed. Understanding the factors and mechanisms that differentiate the GvL effect from GvHD will help in the development of newer treatment modalities.
Authors: Christoph Schmid; Michael Schleuning; Georg Ledderose; Johanna Tischer; Hans-Jochem Kolb Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: N W C J van de Donk; N Kröger; U Hegenbart; P Corradini; J F San Miguel; H Goldschmidt; J A Perez-Simon; M Zijlmans; R A Raymakers; V Montefusco; F A Ayuk; M H J van Oers; A Nagler; L F Verdonck; H M Lokhorst Journal: Bone Marrow Transplant Date: 2006-06 Impact factor: 5.483
Authors: Jeffrey S Miller; Daniel J Weisdorf; Linda J Burns; Arne Slungaard; John E Wagner; Michael R Verneris; Sarah Cooley; Rosanna Wangen; Susan K Fautsch; Roby Nicklow; Todd Defor; Bruce R Blazar Journal: Blood Date: 2007-06-19 Impact factor: 22.113
Authors: Karl S Peggs; Anna Sureda; Wendi Qian; Dolores Caballero; Ann Hunter; Alvaro Urbano-Ispizua; James Cavet; Josep M Ribera; Anne Parker; Miguel Canales; Premini Mahendra; Javier Garcia-Conde; Donald Milligan; Guillermo Sanz; Kirsty Thomson; Reyes Arranz; Anthony H Goldstone; Ivan Alvarez; David C Linch; Jorge Sierra; Stephen Mackinnon Journal: Br J Haematol Date: 2007-10 Impact factor: 6.998
Authors: H Levenga; S Levison-Keating; A V Schattenberg; H Dolstra; N Schaap; R A Raymakers Journal: Bone Marrow Transplant Date: 2007-06-11 Impact factor: 5.483
Authors: Emma Morris; Kirsty Thomson; Charles Craddock; Prem Mahendra; Donald Milligan; Gordon Cook; Graeme Murray Smith; Anne Parker; Steve Schey; Rajesh Chopra; Christopher Hatton; Jane Tighe; Anne Hunter; Karl Peggs; David Linch; Anthony Goldstone; Stephen Mackinnon Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid Journal: Biol Blood Marrow Transplant Date: 2013-09-07 Impact factor: 5.742
Authors: J J Scarisbrick; F L Dignan; S Tulpule; E D Gupta; S Kolade; B Shaw; F Evison; G Shah; E Tholouli; G Mufti; A Pagliuca; R Malladi; K Raj Journal: Bone Marrow Transplant Date: 2014-10-13 Impact factor: 5.483
Authors: Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg Journal: J Clin Invest Date: 2017-01-09 Impact factor: 14.808
Authors: Virginia Fisher; Hanh Khuu; Virginia David-Ocampo; Karen Byrne; Steven Pavletic; Michael Bishop; Daniel H Fowler; A John Barrett; David F Stroncek Journal: Transfusion Date: 2013-10-10 Impact factor: 3.157
Authors: J Gozdzik; K Rewucka; A Krasowska-Kwiecien; A Pieczonka; R Debski; A Zaucha-Prazmo; K Drabko; J Krukowska-Jaros; M Wozniak; J Kowalczyk; M Wysocki; E Gorczynska; K Kalwak; A Chybicka; J Wachowiak Journal: Bone Marrow Transplant Date: 2014-10-13 Impact factor: 5.483
Authors: Merav Bar; Brenda M Sandmaier; Yoshihiro Inamoto; Benedetto Bruno; Parameswaran Hari; Thomas Chauncey; Paul J Martin; Rainer Storb; David G Maloney; Barry Storer; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2013-03-21 Impact factor: 5.742